<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036270</url>
  </required_header>
  <id_info>
    <org_study_id>971-ONC-0028-081</org_study_id>
    <secondary_id>A5991026</secondary_id>
    <nct_id>NCT00036270</nct_id>
  </id_info>
  <brief_title>Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane</brief_title>
  <acronym>TEAM</acronym>
  <official_title>Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given
      sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast
      cancer.

      This Pfizer sponsored trial is part of an international collaboration of investigators
      conducting 7 similar yet independent studies in 9 countries. This study is designed to be
      part of the larger TEAM trial where the data from these 7 studies will be combined. A
      pre-specified analysis of the pooled data will be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years</measure>
    <time_frame>Baseline (Month 0) up to 2.75 years</time_frame>
    <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years</measure>
    <time_frame>Baseline (Month 0) up to 5 years</time_frame>
    <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Events for Overall Survival (OS)</measure>
    <time_frame>Baseline (Month 0) up to 5 years</time_frame>
    <description>Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to New Primary Breast Cancers</measure>
    <time_frame>Baseline (Month 0) up to 5 years</time_frame>
    <description>New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events for Time to Relapse</measure>
    <time_frame>Baseline (Month 0) up to 5 years</time_frame>
    <description>Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Primary Non-breast Cancers</measure>
    <time_frame>Baseline (Month 0) up to 5 years</time_frame>
    <description>Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9779</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tamoxifen + exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane (Aromasin)</intervention_name>
    <description>exemestane, orally, 25 mg, for 5 years</description>
    <arm_group_label>exemestane</arm_group_label>
    <other_name>aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen + exemestane</intervention_name>
    <description>tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy</description>
    <arm_group_label>tamoxifen + exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically confirmed adenocarcinoma of the breast, followed by
             adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if
             indicated.

          -  Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being
             considered.

        Exclusion Criteria:

          -  Those patients not deemed to have had potentially curative primary surgical treatment
             or one of the following criteria:

          -  Inflammatory breast cancer

          -  Histologically positive supraclavicular nodes

          -  Ulceration/infiltration of local skin metastasis

          -  Neoadjuvant chemotherapy

          -  Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion

          -  ER and PR negative primary tumor or ER/PR unknown status.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bessemer</city>
        <state>Alabama</state>
        <zip>35022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Green Valley</city>
        <state>Arizona</state>
        <zip>85614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oro Valley</city>
        <state>Arizona</state>
        <zip>85737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Safford</city>
        <state>Arizona</state>
        <zip>85546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>*0524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Longmont,</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260-</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hudson,</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alton,</city>
        <state>Illinois</state>
        <zip>62002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>ï¿½60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <zip>46037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis,</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shelbyville</city>
        <state>Indiana</state>
        <zip>46176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Adams</city>
        <state>Massachusetts</state>
        <zip>01247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435-2150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102-2389</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woodbury,</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lee's summit</city>
        <state>Missouri</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany,</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam,</city>
        <state>New York</state>
        <zip>12010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brockport</city>
        <state>New York</state>
        <zip>14420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Canandaigua</city>
        <state>New York</state>
        <zip>14424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Geneva</city>
        <state>New York</state>
        <zip>14456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hudson</city>
        <state>New York</state>
        <zip>12534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110-0610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rexford,</city>
        <state>New York</state>
        <zip>12148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Troy,</city>
        <state>New York</state>
        <zip>12180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kernersville</city>
        <state>North Carolina</state>
        <zip>27284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>North Carolina</state>
        <zip>27295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seneca</city>
        <state>North Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bartlesville</city>
        <state>Oklahoma</state>
        <zip>74006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Noman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-5020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma city</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-4416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704-5535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Easley,</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606-5208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702-1449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022`</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-2510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fredericksburg</city>
        <state>Texas</state>
        <zip>78624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061-224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kerrville,</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460-5004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075-7787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio,</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258-3912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>TX 75090-0504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Weslaco</city>
        <state>Texas</state>
        <zip>78596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Christianburg,</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Christianburg</city>
        <state>Virginia</state>
        <zip>24073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hampton,</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pulaski</city>
        <state>Virginia</state>
        <zip>24301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Williamsburg,</city>
        <state>Virginia</state>
        <zip>23188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22191</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wytheville</city>
        <state>Virginia</state>
        <zip>24382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burien,</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133-8414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684-6930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=971-ONC-0028-081</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2002</study_first_submitted>
  <study_first_submitted_qc>May 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2002</study_first_posted>
  <results_first_submitted>October 30, 2009</results_first_submitted>
  <results_first_submitted_qc>November 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2009</results_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane</title>
          <description>Exemestane (AromasinÂ®) 25 milligram (mg) once daily (QD) for 5 years.</description>
        </group>
        <group group_id="P2">
          <title>Tamoxifen Followed by Exemestane</title>
          <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized to Study Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4904"/>
                <participants group_id="P2" count="4875"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4898"/>
                <participants group_id="P2" count="4868"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Treatment to 5 Year Report</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4898"/>
                <participants group_id="P2" count="4868"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="4852"/>
                <participants group_id="P2" count="4814"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2333"/>
                <participants group_id="P2" count="1380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2565"/>
                <participants group_id="P2" count="3488"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="1081"/>
                <participants group_id="P2" count="736"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease- Free Survival (DFS) event</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
                <participants group_id="P2" count="447"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="782"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="288"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment refusal</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too early switch</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No/too late switch/refusal to switch</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="750"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane</title>
          <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
        </group>
        <group group_id="B2">
          <title>Tamoxifen Followed by Exemestane</title>
          <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4898"/>
            <count group_id="B2" value="4868"/>
            <count group_id="B3" value="9766"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="9"/>
                    <measurement group_id="B2" value="64" spread="9"/>
                    <measurement group_id="B3" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1510"/>
                    <measurement group_id="B2" value="1507"/>
                    <measurement group_id="B3" value="3017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1835"/>
                    <measurement group_id="B2" value="1896"/>
                    <measurement group_id="B3" value="3731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than and equal to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1382"/>
                    <measurement group_id="B2" value="1305"/>
                    <measurement group_id="B3" value="2687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4898"/>
                    <measurement group_id="B2" value="4868"/>
                    <measurement group_id="B3" value="9766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years</title>
        <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
        <time_frame>Baseline (Month 0) up to 2.75 years</time_frame>
        <population>Intent-to-Treat (ITT) population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at 2.75 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years</title>
          <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
          <population>Intent-to-Treat (ITT) population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at 2.75 years.</population>
          <units>Events (disease relapse or death)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4898"/>
                <count group_id="O2" value="4868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 2.75 years post-randomization. Null hypothesis: no difference in DFS between the two treatments for the first 2.75 years.
To maintain overall alpha of 0.05, 2 adjustments made: first, a nominal alpha of 0.0302 was used for the primary endpoint. Second, level of significant was 0.0012 for interim analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank (Mantel-Cox). Adjusted for overall stratification factor; 1 degree of freedom.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 favors the test treatment (exemestane only arm).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years</title>
        <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
        <time_frame>Baseline (Month 0) up to 5 years</time_frame>
        <population>ITT population included all participants who were randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years</title>
          <description>Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.</description>
          <population>ITT population included all participants who were randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
          <units>Events (disease relapse or death)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4898"/>
                <count group_id="O2" value="4868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712"/>
                    <measurement group_id="O2" value="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 5 years post-randomization. Null hypothesis: no difference in DFS between the two treatments for the first 5 years.
To maintain overall alpha of 0.05, a nominal alpha of 0.0302 was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank (Mantel-Cox). Adjusted for overall stratification factor; 1 degree of freedom.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 favors the test treatment (exemestane only arm).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events for Overall Survival (OS)</title>
        <description>Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.</description>
        <time_frame>Baseline (Month 0) up to 5 years</time_frame>
        <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events for Overall Survival (OS)</title>
          <description>Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.</description>
          <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
          <units>Events (death)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4898"/>
                <count group_id="O2" value="4868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485"/>
                    <measurement group_id="O2" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 5 years post-randomization. Null hypothesis: no difference in OS between the two treatments for the first 5 years. Overall alpha of 0.05 was maintained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank (Mantel-Cox). Adjusted for overall stratification factor; 1 degree of freedom.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 favors the test treatment (exemestane only arm).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to New Primary Breast Cancers</title>
        <description>New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).</description>
        <time_frame>Baseline (Month 0) up to 5 years</time_frame>
        <population>Data was not analyzed due to insufficient number of events reported for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to New Primary Breast Cancers</title>
          <description>New primary breast cancers were defined as events of ipsilateral/contralateral breast cancer (CBC).</description>
          <population>Data was not analyzed due to insufficient number of events reported for the endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events for Time to Relapse</title>
        <description>Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.</description>
        <time_frame>Baseline (Month 0) up to 5 years</time_frame>
        <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events for Time to Relapse</title>
          <description>Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer.</description>
          <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
          <units>Events (disease relapse)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4898"/>
                <count group_id="O2" value="4868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499"/>
                    <measurement group_id="O2" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis at 5 years post-randomization. Null hypothesis: no difference in time to relapse between the two treatments for the first 5 years. Overall alpha of 0.05 was maintained.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.293</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank (Mantel-Cox). Adjusted for overall stratification factor; 1 degree of freedom.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 favors the test treatment (exemestane only arm).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Primary Non-breast Cancers</title>
        <description>Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.</description>
        <time_frame>Baseline (Month 0) up to 5 years</time_frame>
        <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane</title>
            <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen Followed by Exemestane</title>
            <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Primary Non-breast Cancers</title>
          <description>Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types.</description>
          <population>ITT population: participants randomized to one of the two study arms (all randomized participants); (n) = number of participants at observation for exemestane and tamoxifen, respectively. All participants were censored at the data cut off date of 08 November 2009.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4898"/>
                <count group_id="O2" value="4868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Colorectal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrial cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DCIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other primary cancer types</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tamoxifen Followed by Exemestane</title>
          <description>Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.</description>
        </group>
        <group group_id="E2">
          <title>Exemestane</title>
          <description>Exemestane (AromasinÂ®) 25 mg QD for 5 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="784" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="831" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cytotoxic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous polyposis coli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Congenital musculoskeletal anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skull malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spine malformation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Crohnâs disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mesenteric occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oesophageal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Calcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fat tissue increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Implant site fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oedema due to cardiac disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sense of oppression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Radiation fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Blood test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>CSF test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carbohydrate antigen 15-3 increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coagulation test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Prothrombin level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Enzyme abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>CREST syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoporosis postmenopausal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Systemic sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign lymph node neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Benign respiratory tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bowenâs disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Contralateral breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dermatofibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastases to stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Muellerâs mixed tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neoplasm recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pagetâs disease of the breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimerâs type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>IIIrd nerve paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometrial atrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometrial disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vulval oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vulvovaginal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bile duct stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast lump removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cast application</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cholelithotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Colporrhaphy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Drug therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Eventration procedure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Female genital operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Gastric operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemangioma removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lipoma excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Phlebectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Prolapse repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Radical hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Retinal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Simple mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroid nodule removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine dilation and curettage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Uterine prolapse repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vascular operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Venoocclusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3551" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="3567" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="274" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="482" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="419" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="800" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="796" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="492" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="541" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="415" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1002" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1157" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="269" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="360" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="364" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="428" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="243" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="372" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="369" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="174" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="417" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="404" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="452" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="549" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="316" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="223" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="329" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1690" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="1517" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="291" subjects_at_risk="4852"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="4814"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="4852"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Overall Survival was reported as number of events which otherwise reported as time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

